Clinical phase Alzheimer’s disease drugs 2022, by sponsor
As of end-January 2022, half of all Alzheimer’s disease drugs clinical trial phases worldwide were sponsored by the biopharma industry, while around 28 percent were sponsored by academic medical centers. This statistic illustrates the trial sponsor for each phase of Alzheimer’s disease drug development worldwide as of early 2022, by sponsor.
